Fate Therapeutics Inc (FATE)
3.80
-0.07
(-1.81%)
USD |
NASDAQ |
Apr 26, 16:00
3.795
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Free Cash Flow: -138.42M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -138.42M |
| September 30, 2023 | -183.66M |
| June 30, 2023 | -208.55M |
| March 31, 2023 | -241.14M |
| December 31, 2022 | -283.77M |
| September 30, 2022 | -290.37M |
| June 30, 2022 | -274.76M |
| March 31, 2022 | -257.19M |
| December 31, 2021 | -213.57M |
| September 30, 2021 | -147.85M |
| June 30, 2021 | -131.42M |
| March 31, 2021 | -47.50M |
| December 31, 2020 | -44.16M |
| September 30, 2020 | -49.35M |
| June 30, 2020 | -38.76M |
| March 31, 2020 | -99.07M |
| December 31, 2019 | -90.57M |
| September 30, 2019 | -74.58M |
| June 30, 2019 | -57.76M |
| March 31, 2019 | -47.46M |
| December 31, 2018 | -40.95M |
| Date | Value |
|---|---|
| September 30, 2018 | -40.33M |
| June 30, 2018 | -46.18M |
| March 31, 2018 | -43.67M |
| December 31, 2017 | -38.54M |
| September 30, 2017 | -34.62M |
| June 30, 2017 | -32.03M |
| March 31, 2017 | -30.46M |
| December 31, 2016 | -30.28M |
| September 30, 2016 | -29.84M |
| June 30, 2016 | -30.07M |
| March 31, 2016 | -20.50M |
| December 31, 2015 | -19.90M |
| September 30, 2015 | -19.17M |
| June 30, 2015 | -17.09M |
| March 31, 2015 | -24.48M |
| December 31, 2014 | -23.30M |
| September 30, 2014 | -21.60M |
| June 30, 2014 | -19.39M |
| March 31, 2014 | -17.33M |
| December 31, 2013 | -15.62M |
Free Cash Flow Range, Past 5 Years
-290.37M
Minimum
Sep 2022
-38.76M
Maximum
Jun 2020
-151.18M
Average
-138.42M
Median
Dec 2023
Free Cash Flow Benchmarks
| Amicus Therapeutics Inc | -76.53M |
| Regeneron Pharmaceuticals Inc | 3.668B |
| Sarepta Therapeutics Inc | -588.34M |
| ADMA Biologics Inc | 3.819M |
| Ocular Therapeutix Inc | -76.32M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -36.64M |
| Cash from Investing (Quarterly) | 45.35M |
| Cash from Financing (Quarterly) | -0.18M |
| Free Cash Flow Per Share (Quarterly) | -0.3733 |
| Free Cash Flow to Equity (Quarterly) | -36.82M |
| Free Cash Flow Yield | -37.01% |